By performing retrospective analysis of the AVAglio trial, Sandmann et al revealed that GBM patients with IDH1 mutation and PN subtype were more likely to obtain OS benefit from BEV therapy during first-line treatment [36]. The gene discussed is IDH1; the disease is glioblastoma.